Pretreatment characteristics
| Pretreatment characteristic . | Value . | Complete response (%) . |
|---|---|---|
| Median age, y (range) | 57 (17-86) | — |
| Younger than 60 y | 186 (62) | 140 (75) |
| 60 to 69 y | 73 (24) | 56 (77) |
| 70 y or older | 41 (14) | 21 (51) |
| Male | 211 (70) | 154 (73) |
| Female | 89 (30) | 63 (71) |
| Median time from diagnosis, mo (range) | 24 (0-155) | — |
| Rai stage 0 | 11 (4) | 10 (91) |
| Rai stages I to II | 182 (61) | 136 (75) |
| Rai stages III to IV | 107 (36) | 71 (66) |
| Zubrod performance status 0 | 119 (40) | 96 (81) |
| Zubrod performance status 1 | 171 (57) | 116 (68) |
| Zubrod performance status 2 | 10 (3) | 5 (50) |
| Median white cell count ×109/L (range) | 76 (2-620) | — |
| Less than 50 ×109/L | 110 (37) | 82 (75) |
| 50 to 149 ×109/L | 139 (46) | 107 (77) |
| 150 ×109/L or more | 51 (17) | 28 (55) |
| Median serum β2-microglobulin, mg/L (range) | 3.7 (1.6-16.4) | — |
| Less than 2× upper limit normal | 168 (57) | 141 (84) |
| 2× or more upper limit normal | 127 (43) | 73 (58) |
| Median serum lactate dehydrogenase, IU/L (range) | 548 (103-1828) | — |
| Less than 2× upper limit normal (%) | 293 (98) | 72 (71) |
| 2× or more upper limit normal (%) | 6 (2) | 2 (33) |
| Diploid cytogenetics | 156 (70) | 118 (76) |
| Abnormal cytogenetics, not chromosome 17 | 58 (26) | 42 (72) |
| Abnormality of chromosome 17 | 8 (4) | 2 (25) |
| Bone marrow lymphocyte CD19/38 less than 30% | 201 (79) | 150 (75) |
| Bone marrow lymphocyte CD19/38 30% or more | 52 (21) | 34 (65) |
| Pretreatment characteristic . | Value . | Complete response (%) . |
|---|---|---|
| Median age, y (range) | 57 (17-86) | — |
| Younger than 60 y | 186 (62) | 140 (75) |
| 60 to 69 y | 73 (24) | 56 (77) |
| 70 y or older | 41 (14) | 21 (51) |
| Male | 211 (70) | 154 (73) |
| Female | 89 (30) | 63 (71) |
| Median time from diagnosis, mo (range) | 24 (0-155) | — |
| Rai stage 0 | 11 (4) | 10 (91) |
| Rai stages I to II | 182 (61) | 136 (75) |
| Rai stages III to IV | 107 (36) | 71 (66) |
| Zubrod performance status 0 | 119 (40) | 96 (81) |
| Zubrod performance status 1 | 171 (57) | 116 (68) |
| Zubrod performance status 2 | 10 (3) | 5 (50) |
| Median white cell count ×109/L (range) | 76 (2-620) | — |
| Less than 50 ×109/L | 110 (37) | 82 (75) |
| 50 to 149 ×109/L | 139 (46) | 107 (77) |
| 150 ×109/L or more | 51 (17) | 28 (55) |
| Median serum β2-microglobulin, mg/L (range) | 3.7 (1.6-16.4) | — |
| Less than 2× upper limit normal | 168 (57) | 141 (84) |
| 2× or more upper limit normal | 127 (43) | 73 (58) |
| Median serum lactate dehydrogenase, IU/L (range) | 548 (103-1828) | — |
| Less than 2× upper limit normal (%) | 293 (98) | 72 (71) |
| 2× or more upper limit normal (%) | 6 (2) | 2 (33) |
| Diploid cytogenetics | 156 (70) | 118 (76) |
| Abnormal cytogenetics, not chromosome 17 | 58 (26) | 42 (72) |
| Abnormality of chromosome 17 | 8 (4) | 2 (25) |
| Bone marrow lymphocyte CD19/38 less than 30% | 201 (79) | 150 (75) |
| Bone marrow lymphocyte CD19/38 30% or more | 52 (21) | 34 (65) |
Data are numbers (%) except where specified.